Patent ID: 8106061

Claim:
A method of treating a prostatic disease selected from the group consisting of benign prostatic hyperplasia and prostatism, comprising administering a selective inhibitor of phosphodiesterase IV and/or phosphodiesterase V to a subject having said prostatic disease selected from the group consisting of benign prostatic hyperplasia and prostatism, wherein said inhibitor is selected from the group consisting of: a) 2-(N-(4-carboxypiperidine)-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline; b) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate; c) 4-((3,4,-(methylendioxy)benzyl)amino)-6,7,8-trimethoxy-quinazoline; d) 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine; e) 2-n-butyl-5-chloro-1-(2-chlorobenzyl) 4-methylacetate-imidazole; and f) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one; and whereby said administration treats said prostatic disease selected from the group consisting of benign prostatic hyperplasia and prostatism.